CagriSema (cagrilintide 2.4 mg / semaglutide 2.4 mg) is an investigational once-weekly injectable fixed-dose combination that pairs a long-acting amylin analogue with a GLP-1 receptor agonist. Novo Nordisk submitted a New Drug Application (NDA) to the FDA in December 2025 for weight management, and a regulatory decision is expected by late 2026.
If approved, CagriSema would become the first GLP-1/amylin combination product on the market. This pipeline evidence review is for payer strategists, formulary committees, access teams, and commercial analysts who need to understand the clinical data, competitive positioning, and access implications before launch.
Mechanism: why GLP-1 plus amylin
GLP-1 receptor agonists (semaglutide, tirzepatide, orforglipron) suppress appetite by activating GLP-1 receptors in the brain and delaying gastric emptying. Amylin is a hormone co-secreted with insulin that activates satiety centers in the brain and further slows gastric emptying through a complementary pathway.
By combining semaglutide (GLP-1 receptor agonism) with cagrilintide (amylin receptor agonism), CagriSema targets two distinct appetite-regulating mechanisms simultaneously. The rationale is additive or synergistic weight loss beyond what either agent achieves alone.
This is a different dual-target approach than tirzepatide (which combines GLP-1 and GIP receptor agonism), and the clinical question is whether the GLP-1/amylin combination offers meaningful advantages over the GLP-1/GIP approach.
REDEFINE 1: obesity without type 2 diabetes
REDEFINE 1 was a 68-week, phase 3, randomized, double-blind, placebo- and active-controlled trial in 3,417 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with one or more obesity-related complications, without type 2 diabetes. Participants were randomized 21:3:3:7 to CagriSema, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo.
Key results (treatment-regimen estimand):
- CagriSema: −20.4% mean body weight reduction at 68 weeks
- Semaglutide alone: served as active comparator
- Cagrilintide alone: served as active comparator
- Placebo: −3.0%
- Estimated difference vs. placebo: −17.3 percentage points (p < 0.001)
Treatment-effect estimand (if all patients stayed on treatment):
- CagriSema: −22.7%
- Placebo: −2.3%
Response rates (CagriSema group):
- ≥5% weight loss: 91.9% (vs. 31.5% placebo)
- ≥20% weight loss: 53.6%
- ≥25% weight loss: 34.7%
These data were published in the New England Journal of Medicine in 2025.
REDEFINE 2: obesity with type 2 diabetes
REDEFINE 2 was a 68-week, phase 3, randomized, double-blind, placebo-controlled trial in 1,206 adults with type 2 diabetes and obesity (BMI ≥30) or overweight (BMI ≥27).
Key results:
- CagriSema: −13.7% mean body weight at 68 weeks
- Placebo: −3.4%
- Estimated difference: −10.4 percentage points (p < 0.001)
- 74% of CagriSema patients achieved HbA1c ≤6.5% vs. 15.9% with placebo
REDEFINE 2 demonstrated both meaningful weight loss and glycemic control in the type 2 diabetes population.
REDEFINE 4: head-to-head versus tirzepatide
REDEFINE 4 was an 84-week, open-label, randomized phase 3 trial comparing CagriSema (cagrilintide 2.4 mg / semaglutide 2.4 mg) with tirzepatide 15 mg in 809 adults with obesity.
Key results (announced February 23, 2026):
- CagriSema: 23% mean weight loss at 84 weeks
- The primary endpoint — non-inferiority of CagriSema vs. tirzepatide on weight loss — was not met
- Novo Nordisk characterized the result as clinically meaningful additive weight loss beyond GLP-1 biology alone
The missed primary endpoint in REDEFINE 4 is notable. CagriSema achieved impressive absolute weight loss (23%), but did not demonstrate statistical non-inferiority against tirzepatide 15 mg at 84 weeks. This head-to-head comparison will be important for payer decision-making when both therapies compete for formulary position.
REIMAGINE 2: type 2 diabetes monotherapy comparison
On February 2, 2026, Novo Nordisk announced results from REIMAGINE 2, a phase 3 trial in adults with type 2 diabetes. CagriSema demonstrated superior HbA1c reduction of 1.91 percentage points and weight loss of 14.2% versus semaglutide across all tested doses. Novo Nordisk indicated it will approach regulatory authorities to discuss the pathway for CagriSema in type 2 diabetes separately from the obesity NDA.
Safety profile
A meta-analysis of three randomized controlled trials (n=3,545) published in 2026 found:
- CagriSema produced significantly greater percentage weight loss than semaglutide (mean difference −7.47%, p < 0.001)
- Overall and serious adverse events were comparable between CagriSema and semaglutide
- CagriSema had increased injection-site conditions (RR 3.27, 95% CI 1.27–8.46) and nausea (RR 1.64, 95% CI 1.01–2.66) relative to semaglutide
- LDL-C was modestly higher with CagriSema vs. semaglutide (mean difference 0.29 mmol/L, p = 0.03)
REDEFINE 3, the cardiovascular outcomes trial, is ongoing. CV-endpoint data are not yet available, which may be a consideration for payers evaluating CagriSema against semaglutide (SELECT trial, CV benefit demonstrated) and tirzepatide (SURPASS-CVOT, CV outcomes data available).
Competitive positioning
| Parameter | CagriSema (pipeline) | Wegovy (semaglutide) | Zepbound (tirzepatide) | Foundayo (orforglipron) |
|---|---|---|---|---|
| Mechanism | GLP-1 + Amylin | GLP-1 | GLP-1 + GIP | GLP-1 (oral, small molecule) |
| Route | Once-weekly injection | Once-weekly injection | Once-weekly injection | Once-daily oral tablet |
| Weight loss (max) | 20–23% (68–84 weeks) | ~15% (68 weeks) | ~20–22% (72 weeks) | ~12.4% (72 weeks) |
| FDA status | NDA under review | Approved | Approved | Approved (April 2026) |
| CV outcomes data | Pending (REDEFINE 3) | Positive (SELECT) | Positive (SURPASS-CVOT) | Positive (ACHIEVE-4) |
CagriSema's weight-loss numbers are strong but occupy a range similar to tirzepatide. The differentiating question for payers will be whether the amylin mechanism offers enough incremental benefit to justify a distinct formulary position, particularly given the absence of CV outcomes data at launch.
Pricing and access outlook
CagriSema's WAC pricing has not been announced. For context:
- Wegovy (semaglutide 2.4 mg) WAC: approximately $1,349/month
- Zepbound (tirzepatide) WAC: approximately $1,059/month
- Foundayo (orforglipron) self-pay: $149–$349/month
Novo Nordisk will need to price CagriSema competitively against both its own Wegovy franchise and Lilly's Zepbound. In February 2026, the same week Novo Nordisk announced REDEFINE 4 results, the company also announced it would cut the US list price of Wegovy by 50% and Ozempic by 35%, effective January 2027, in an effort to expand access. This creates a complex pricing environment: CagriSema must be positioned above the now-cheaper Wegovy to justify the amylin mechanism, but not so far above that payers reject it in favor of tirzepatide.
If CagriSema is priced at a premium to Wegovy, payers will likely require documentation that the patient failed or was intolerant to both a GLP-1 monotherapy and a GIP/GLP-1 combination (tirzepatide) before approving CagriSema — a high step-therapy bar. If priced at parity or below Wegovy, CagriSema could capture share as a preferred injectable option, especially in patients who have not yet tried any GLP-1 therapy.
What access teams should prepare
- Watch the FDA decision timeline. The NDA was submitted December 2025; a decision is expected by late 2026. If approved, the launch could coincide with 2027 formulary planning cycles.
- Monitor REDEFINE 3 cardiovascular outcomes data. The absence of CV outcomes at launch is a potential payer objection. If REDEFINE 3 reads out positive before or shortly after approval, it strengthens the access case significantly.
- Prepare for step-therapy protocols. Given the crowded GLP-1 market (Wegovy, Zepbound, Foundayo, Wegovy pill), payers are likely to implement sequential step-therapy: oral GLP-1 → injectable GLP-1 monotherapy → dual-mechanism (tirzepatide or CagriSema).
- Track the REDEFINE 4 implications. The missed non-inferiority endpoint against tirzepatide gives payers a data point to prefer tirzepatide over CagriSema, or to require a trial of tirzepatide first. Access teams should prepare counter-arguments based on patient-specific factors.
- Monitor the type 2 diabetes regulatory pathway. Novo Nordisk's separate REIMAGINE program for type 2 diabetes could lead to a second indication. If approved for both obesity and T2D, CagriSema's total addressable market and payer leverage increase substantially.
Sources
- Novo Nordisk. Novo Nordisk Files for FDA Approval of CagriSema. Press release, December 18, 2025. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916470
- Novo Nordisk. CagriSema Demonstrated 23% Weight Loss in REDEFINE 4. Press release, February 23, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916481
- Novo Nordisk. CagriSema Demonstrated Superior HbA1c Reduction and Weight Loss in REIMAGINE 2. Press release, February 2, 2026.
- American College of Cardiology. REDEFINE 1 and REDEFINE 2: Greater Weight Loss With Combined Cagrilintide-Semaglutide. Journal scan, 2025. https://www.acc.org/latest-in-cardiology/journal-scans/2025/07/02/14/43/redefine-1-and-redefine-2
- PubMed. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. 2026. https://pubmed.ncbi.nlm.nih.gov/41834765
- PR Newswire. Novo Nordisk Files for FDA Approval of CagriSema. December 18, 2025. https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
- Renal and Urology News. REDEFINE 4: CagriSema Weight Loss Results Compared With Tirzepatide. February 2026. https://www.renalandurologynews.com/news/redefine-4-cagrisema-weight-loss-results-compared-with-tirzepatide
- Milliman. 4 Pending FDA Approvals Payers, PBMs, and Market Access Teams Should Be Preparing For Now. 2026. https://www.milliman.com/en/insight/4-pending-fda-approvals-payers-pbms-market-access-teams
